OCCIDENT
Venture capital
UncertainLast verified 6 Nov 2026
OCCIDENT is a venture capital investor financing deep tech and life sciences startups in Germany, Switzerland, and internationally, with initial tickets of 500k to 1m at Seed and Series A.
1 deal in the last 24 months, latest 3 Nov 2025. From its website and its deals in the news.
Key facts
- Stages
- Seed, Series A, Series C+
- Sectors
- Biotech & pharma, Healthtech, Other deeptech
- Ticket
- €500K–€1M
- Eligible countries
- Not stated
- Provider based in
- Switzerland
- Timing
- Rolling applications
- Focus
- deep tech; life sciences; oncology; neurology; rare diseases
- How to apply
- Application form · Apply on their site
Recent deals
| Company | Round | Sectors | Amount | Role | Announced |
|---|---|---|---|---|---|
| Tubulis | Series C+ | Biotech & pharma, Healthtech | €344M | participant | 3 Nov 2025 |
Evidence
Short excerpts from the sources, in their original language, that back the facts above.
- Apply link
https://www.occident.group/en/pitch-deck-submission | Submit your pitch deck now
https://www.occident.group/en/for-founders - Kind
As a venture capital investor
https://www.occident.group/en/for-founders - Sectors
deep tech start-ups in the life sciences sector
https://www.occident.group/en/for-founders - Stages
For an initial investment, we focus on Seed and Series A.
https://www.occident.group/en/for-founders - Ticket
start at 500,000 to 1,000,000
https://www.occident.group/en/for-founders - Ticket
start at 500,000 to 1,000,000
https://www.occident.group/en/for-founders
Status history
- 7 Nov 2026: Rolling → Uncertain (profiles: investor activity)
- 6 Nov 2026: Rolling → Uncertain (freshness: investor activity)
- 6 Nov 2026: Rolling (first extraction)
- 6 Nov 2026: Uncertain → Rolling (profiles: investor activity)
Something wrong or out of date? Report an error.
Work at OCCIDENT? Claim this profile to confirm what you invest in.